RESUMEN
BACKGROUND: The immune checkpoint protein programmed cell death ligand 1 (PD-L1) binds to PD1 to promote tumor cell escape from the killing effect of the immune system. However, there are few studies on the regulatory mechanisms of PD-L1 in tumors. Although PD-L1 has been reported to undergo ubiquitination in some cancers, its regulatory mechanisms in oral squamous cell carcinoma (OSCC) are unclear. Therefore, we aimed to investigate this phenomenon. METHODS: We examined the expression and function of USP9X and PD-L1 in human oral keratinocytes (HOK) and OSCC cell lines (HN4 and HN30) as the control and relevant cancer cells using western blotting, immunoprecipitation, immunohistochemistry (IHC), T-cell-mediated tumor cell killing assay, and liquid chromatography-mass spectrometry. RESULTS: Programmed cell death ligand 1 was highly expressed in OSCC by the regulation of the ubiquitin-proteasome pathway. Furthermore, we discovered that ubiquitin-specific peptidase 9, X-linked (USP9X) could be combined with PD-L1 to induce its deubiquitination and stabilize its protein expression in OSCC. CONCLUSION: Our data indicate that USP9X deubiquitinates and stabilizes PD-L1. Suppressing the expression of USP9X blocks tumor cell growth. The results provide a theoretical basis for USP9X as a therapeutic target.
Asunto(s)
Antígeno B7-H1/metabolismo , Carcinoma de Células Escamosas/metabolismo , Neoplasias de la Boca/metabolismo , Ubiquitina Tiolesterasa/metabolismo , Antígeno B7-H1/genética , Biomarcadores , Carcinoma de Células Escamosas/genética , Expresión Génica , Humanos , Queratinocitos/metabolismo , Neoplasias de la Boca/genética , Unión Proteica , Estabilidad Proteica , Ubiquitina Tiolesterasa/genética , UbiquitinaciónRESUMEN
Compared to normal counterparts,cancer cells exhibit metabolic changes owing to both genetic and epigenetic alterations. Some abnormal alterations happen in tumor cells including glycolysis,mito-chondrial biogenesis,glutaminolysis and lipid synthesis. These metabolic changes have great significance to development of tumor and clinical targeted therapies.